Immix Biopharma, INC DEF 14A proxy statements

Immix Biopharma, Inc. has issued a proxy statement for its 2026 Annual Meeting of Stockholders, detailing proposals for director elections and auditor ratification.

Immix Biopharma files a supplement to its proxy statement to include Inline XBRL tagging for insider trading and equity grant policies, and to add a description of its clawback policy.

Immix Biopharma announces its annual stockholders meeting to be held on June 20, 2025, featuring the election of eight directors and ratification of its accounting firm.

Immix Biopharma announces its 2025 annual meeting of stockholders to elect directors and ratify the appointment of its independent auditor.

Immix Biopharma, Inc. has filed a definitive proxy statement with the SEC.

Immix Biopharma announces its annual stockholders meeting to be held on June 11, 2024, to elect directors, ratify the appointment of its accounting firm, and approve amendments to its equity incentive plan.